Pablo Garcia-Pavia

List of Publications by Year
in descending order

155 papers	8,371 citations	44069 48 h-index	53230 85 g-index
169 all docs	169 docs citations	169 times ranked	8924 citing authors

#	Article	IF	Citations
1	Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. European Heart Journal, 2015, 36, 2585-2594.	2.2	789
2	Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2020, 396, 759-769.	13.7	481
3	Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 2021, 42, 1554-1568.	2.2	434
4	Truncating FLNC Mutations Are Associated With High-Risk Dilated and Arrhythmogenic Cardiomyopathies. Journal of the American College of Cardiology, 2016, 68, 2440-2451.	2.8	340
5	Mutations in the NOTCH pathway regulator MIB1 cause left ventricular noncompaction cardiomyopathy. Nature Medicine, 2013, 19, 193-201.	30.7	296
6	Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths. European Heart Journal, 2017, 38, 1895-1904.	2.2	258
7	Familial Evaluation in Arrhythmogenic Right Ventricular Cardiomyopathy. Circulation, 2011, 123, 2701-2709.	1.6	226
8	Genetic Variants Associated With Cancer Therapyâ€“Induced Cardiomyopathy. Circulation, 2019, 140, 31-41.	1.6	195
9	Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice. JACC: Heart Failure, 2019, 7, 709-716.	4.1	188
10	Genetic Etiology for Alcohol-Induced Cardiac Toxicity. Journal of the American College of Cardiology, 2018, 71, 2293-2302.	2.8	182
11	Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease. European Heart Journal, 2017, 38, 2649-2662.	2.2	163
12	Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology <scp>W</scp>orking <scp>G</scp>roup on <scp>M</scp>yocardial and <scp>P</scp>ericardial <scp>D</scp>iseases. European Journal of Heart Failure, 2021, 23, 512-526.	7.1	153
13	International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM). Circulation, 2018, 137, 1015-1023.	1.6	149
14	Development of a Novel Risk Prediction Model for Sudden Cardiac Death in Childhood Hypertrophic Cardiomyopathy (HCM Risk-Kids). JAMA Cardiology, 2019, 4, 918.	6.1	147
15	Association of Sleep Duration and Quality With Subclinical Atherosclerosis. Journal of the American College of Cardiology, 2019, 73, 134-144.	2.8	145
16	Multiparametric Echocardiography Scores for the Diagnosis of CardiacÂAmyloidosis. JACC: Cardiovascular Imaging, 2020, 13, 909-920.	5.3	136
17	Alcoholic cardiomyopathy. World Journal of Cardiology, 2014, 6, 771.	1.5	116
18	Calmodulin mutations and life-threatening cardiac arrhythmias: insights from the International Calmodulinopathy Registry. European Heart Journal, 2019, 40, 2964-2975.	2.2	116

#	Article	IF	Citations
19	Prediction of thromboâ€embolic risk in patients with hypertrophic cardiomyopathy (<scp>HCM</scp>) Tj ETQq1 1 0.784314 rgBT /Over	7.1	114
20	Genetically Confirmed Familial Hypercholesterolemia in Patients With Acute Coronary Syndrome. Journal of the American College of Cardiology, 2017, 70, 1732-1740.	2.8	111
21	Efficacy and safety of tafamidis doses in the <scp>Tafamidis in Transthyretin Cardiomyopathy Clinical Trial</scp> (<scp>ATTRâ€ACT</scp>) and longâ€term extension study. European Journal of Heart Failure, 2021, 23, 277-285.	7.1	103
22	The Cardiomyopathy Registry of the EURObservational Research Programme of the European Society of Cardiology: baseline data and contemporary management of adult patients with cardiomyopathies. European Heart Journal, 2018, 39, 1784-1793.	2.2	94
23	Dilated Cardiomyopathy DueÂtoÂBLC2-Associated AthanogeneÂ3Â(BAG3)ÂMutations. Journal of the American College of Cardiology, 2018, 72, 2471-2481.	2.8	93
24	Assessment of Microcirculatory Remodeling With Intracoronary Flow Velocity and Pressure Measurements. Circulation, 2009, 120, 1561-1568.	1.6	83
25	Desmosomal protein gene mutations in patients with idiopathic dilated cardiomyopathy undergoing cardiac transplantation: a clinicopathological study. Heart, 2011, 97, 1744-1752.	2.9	82
26	DiagnÃ³stico y tratamiento de la amiloidosis cardiaca por transtiretina. Progreso y esperanza. Revista Espanola De Cardiologia, 2017, 70, 991-1004.	1.2	79
27	Natural History and Prognostic Factors in Alcoholic Cardiomyopathy. JACC: Heart Failure, 2015, 3, 78-86.	4.1	78
28	The Alternative Heart: Impact of Alternative Splicing in Heart Disease. Journal of Cardiovascular Translational Research, 2013, 6, 945-955.	2.4	76
29	Clinical Phenotypes and Prognosis of Dilated Cardiomyopathy Caused by Truncating Variants in the TTN Gene. Circulation: Heart Failure, 2020, 13, e006832.	3.9	75
30	Prevalence of wild type ATTR assessed as myocardial uptake in bone scan in the elderly population. International Journal of Cardiology, 2018, 270, 192-196.	1.7	69
31	Mortality Among Referral Patients With Hypertrophic Cardiomyopathy vs the General European Population. JAMA Cardiology, 2020, 5, 73.	6.1	69
32	The wide spectrum of POT1 gene variants correlates with multiple cancer types. European Journal of Human Genetics, 2017, 25, 1278-1281.	2.8	66
33	Infective Endocarditis in Patients With Bicuspid Aortic Valve or MitralÂValveÂProlapse. Journal of the American College of Cardiology, 2018, 71, 2731-2740.	2.8	65
34	High Prevalence of Intracardiac Thrombi in Cardiac Amyloidosis. Journal of the American College of Cardiology, 2019, 73, 1733-1734.	2.8	65
35	Differential Gene Expression of Cardiac Ion Channels in Human Dilated Cardiomyopathy. PLoS ONE, 2013, 8, e79792.	2.5	64
36	Hypertrophic remodelling in cardiac regulatory myosin light chain (MYL2) founder mutation carriers. European Heart Journal, 2016, 37, 1815-1822.	2.2	63

#	Article	IF	Citations
37	Time delays in the diagnosis and treatment of Fabry disease. International Journal of Clinical Practice, 2017, 71, e12914.	1.7	62
38	Severe Cardiac Dysfunction and Death Caused by Arrhythmogenic Right Ventricular Cardiomyopathy Type 5 Are Improved by Inhibition of Glycogen Synthase Kinase-3Î². Circulation, 2019, 140, 1188-1204.	1.6	62
39	Phenotypic clustering of dilated cardiomyopathy patients highlights important pathophysiological differences. European Heart Journal, 2021, 42, 162-174.	2.2	62
40	Genetic basis of familial dilated cardiomyopathy patients undergoing heart transplantation. Journal of Heart and Lung Transplantation, 2016, 35, 625-635.	0.6	60
41	Idiopathic Restrictive Cardiomyopathy IsÂPrimarily a GeneticÂDisease. Journal of the American College of Cardiology, 2016, 67, 3021-3023.	2.8	59
42	Formin Homology 2 Domain Containing 3 (FHOD3) Is a Genetic Basis for Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2018, 72, 2457-2467.	2.8	59
43	Genetic basis of endâ€stage hypertrophic cardiomyopathy. European Journal of Heart Failure, 2011, 13, 1193-1201.	7.1	57
44	Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy. European Journal of Heart Failure, 2021, 23, 895-905.	7.1	57
45	Genetics of arrhythmogenic right ventricular cardiomyopathy. Journal of Medical Genetics, 2013, 50, 280-289.	3.2	56
46	Association of Genetic Variants With Outcomes in Patients With Nonischemic Dilated Cardiomyopathy. Journal of the American College of Cardiology, 2021, 78, 1682-1699.	2.8	55
47	Papel de la gammagrafÃa cardiaca con 99mTc-DPD en la discriminaciÃ³n del subtipo de amiloidosis cardiaca. Revista Espanola De Cardiologia, 2012, 65, 440-446.	1.2	54
48	Alpha-protein kinase 3 (ALPK3) truncating variants are a cause of autosomal dominant hypertrophic cardiomyopathy. European Heart Journal, 2021, 42, 3063-3073.	2.2	51
49	Activation of Serine One-Carbon Metabolism by Calcineurin AÎ²1 Reduces Myocardial Hypertrophy and Improves Ventricular Function. Journal of the American College of Cardiology, 2018, 71, 654-667.	2.8	45
50	Clinical Features and Natural History of PRKAG2 Variant Cardiac Glycogenosis. Journal of the American College of Cardiology, 2020, 76, 186-197.	2.8	45
51	Diagnosis and Treatment of Transthyretin Cardiac Amyloidosis. Progress and Hope. Revista Espanola De Cardiologia (English Ed), 2017, 70, 991-1004.	0.6	43
52	Genetics in dilated cardiomyopathy. Biomarkers in Medicine, 2013, 7, 517-533.	1.4	42
53	Direct oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation. International Journal of Cardiology, 2017, 248, 232-238.	1.7	41
54	Loss of SRSF3 in Cardiomyocytes Leads to Decapping of Contraction-Related mRNAs and Severe Systolic Dysfunction. Circulation Research, 2019, 125, 170-183.	4.5	41

#	Article	IF	Citations
55	Importance of genotype for risk stratification in arrhythmogenic right ventricular cardiomyopathy using the 2019 ARVC risk calculator. European Heart Journal, 2022, 43, 3053-3067.	2.2	41
56	Clinical Risk Prediction in Patients With Left Ventricular MyocardialÂNoncompaction. Journal of the American College of Cardiology, 2021, 78, 643-662.	2.8	40
57	Association of Left Ventricular Systolic Dysfunction Among Carriers of Truncating Variants in Filamin C With Frequent Ventricular Arrhythmia and End-stage Heart Failure. JAMA Cardiology, 2021, 6, 891.	6.1	36
58	Critical Comparison of Documents FromÂScientific Societies on CardiacÂAmyloidosis. Journal of the American College of Cardiology, 2022, 79, 1288-1303.	2.8	35
59	Left Ventricular Noncompaction. Journal of the American College of Cardiology, 2014, 64, 1981-1983.	2.8	34
60	No clinically significant valvular regurgitation in longâ€term cabergoline treatment for prolactinoma. Clinical Endocrinology, 2012, 77, 275-280.	2.4	33
61	Prevalence of Cardiac Amyloidosis in Patients with Carpal Tunnel Syndrome. Journal of Cardiovascular Translational Research, 2019, 12, 507-513.	2.4	33
62	Prevalence of cardiac amyloidosis among elderly patients with systolic heart failure or conduction disorders. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 156-163.	3.0	33
63	Perfil clÃnico y evoluciÃ³n de la amiloidosis cardiaca en un centro espaÃ±ol de referencia. Revista Espanola De Cardiologia, 2021, 74, 149-158.	1.2	33
64	Alternative Splicing of NOX4 in the Failing Human Heart. Frontiers in Physiology, 2017, 8, 935.	2.8	32
65	Additional value of screening for minor genes and copy number variants in hypertrophic cardiomyopathy. PLoS ONE, 2017, 12, e0181465.	2.5	32
66	Gene network and familial analyses uncover a gene network involving Tbx5/Osr1/Pcsk6 interaction in the second heart field for atrial septation. Human Molecular Genetics, 2016, 25, 1140-1151.	2.9	31
67	The Calcineurin Variant CnAÎ²1 Controls Mouse Embryonic Stem Cell Differentiation by Directing mTORC2 Membrane Localization and Activation. Cell Chemical Biology, 2016, 23, 1372-1382.	5.2	30
68	Clinical Profile of Cardiac Involvement in Danon Disease. Circulation Genomic and Precision Medicine, 2020, 13, e003117.	3.6	29
69	Clinical characteristics and determinants of the phenotype in TMEM43 arrhythmogenic right ventricular cardiomyopathy type 5. Heart Rhythm, 2020, 17, 945-954.	0.7	28
70	Role of copy number variants in sudden cardiac death and related diseases: genetic analysis and translation into clinical practice. European Journal of Human Genetics, 2018, 26, 1014-1025.	2.8	26
71	Sex-Related Risk of Cardiac Involvement in Hereditary Transthyretin Amyloidosis. JACC: Heart Failure, 2021, 9, 736-746.	4.1	26
72	Malignant ventricular arrhythmias in alcoholic cardiomyopathy. International Journal of Cardiology, 2015, 199, 99-105.	1.7	25

#	Article	IF	Citations
73	Induction of the calcineurin variant CnAÎ²1 after myocardial infarction reduces post-infarction ventricular remodelling by promoting infarct vascularization. Cardiovascular Research, 2014, 102, 396-406.	3.8	24
74	Heart failure entails significant changes in human nucleocytoplasmic transport gene expression. International Journal of Cardiology, 2013, 168, 2837-2843.	1.7	23
75	Systemic embolism in amyloid transthyretin cardiomyopathy. European Journal of Heart Failure, 2022, 24, 1387-1396.	7.1	23
76	Mitochondrial haplogroups associated with end-stage heart failure and coronary allograft vasculopathy in heart transplant patients. European Heart Journal, 2012, 33, 346-353.	2.2	22
77	Stop-Gain Mutations in PKP2 Are Associated with a Later Age of Onset of Arrhythmogenic Right Ventricular Cardiomyopathy. PLoS ONE, 2014, 9, e100560.	2.5	22
78	Psychiatric and cognitive characteristics of individuals with Danon disease (LAMP2 gene) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 54	1.2	22
79	Amiloidosis cardÃaca por transtiretina. Medicina ClÃnica, 2021, 156, 126-134.	0.6	22
80	Predicted pathogenic mutations in STAP1 are not associated with clinically defined familial hypercholesterolemia. Atherosclerosis, 2020, 292, 143-151.	0.8	21
81	Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey. JACC: CardioOncology, 2021, 3, 537-546.	4.0	21
82	Animal models of arrhythmogenic right ventricular cardiomyopathy: what have we learned and where do we go? Insight for therapeutics. Basic Research in Cardiology, 2017, 112, 50.	5.9	20
83	Role of Cardiac Scintigraphy With 99mTc-DPD in the Differentiation of Cardiac Amyloidosis Subtype. Revista Espanola De Cardiologia (English Ed), 2012, 65, 440-446.	0.6	19
84	Gonococcal endocarditis: a case report and review of the literature. Infection, 2014, 42, 425-428.	4.7	19
85	Analysis of diagnostic and therapeutic strategies in advanced cardiac light-chain amyloidosis. Journal of Heart and Lung Transplantation, 2016, 35, 995-1002.	0.6	19
86	Lung ultrasound as a translational approach for non-invasive assessment of heart failure with reduced or preserved ejection fraction in mice. Cardiovascular Research, 2017, 113, 1113-1123.	3.8	19
87	Predictores de riesgo en una cohorte espaÃ±ola con cardiolaminopatÃas. Registro REDLAMINA. Revista Espanola De Cardiologia, 2021, 74, 216-224.	1.2	19
88	Utilidad del anÃ¡lisis genÃ©tico de la miocardiopatÃa hipertrÃ³fica en la prÃ¡ctica real. Revista Espanola De Cardiologia, 2013, 66, 746-747.	1.2	18
89	Testosterone Replacement Therapy in Deficient Patients With Chronic Heart Failure. Journal of Cardiovascular Pharmacology and Therapeutics, 2018, 23, 543-550.	2.0	16
90	Nanomechanical Phenotypes in Cardiac Myosin-Binding Protein C Mutants That Cause Hypertrophic Cardiomyopathy. ACS Nano, 2021, 15, 10203-10216.	14.6	16

#	Article	IF	Citations
91	Mitochondrial tRNA valine as a recurrent target for mutations involved in mitochondrial cardiomyopathies. Mitochondrion, 2012, 12, 357-362.	3.4	15
92	Infective endocarditis in hypertrophic cardiomyopathy. Medicine (United States), 2016, 95, e4008.	1.0	15
93	Plan of Action for Inherited Cardiovascular Diseases: Synthesis of Recommendations and Action Algorithms. Revista Espanola De Cardiologia (English Ed), 2016, 69, 300-309.	0.6	14
94	Prevalence and clinical outcomes of dystrophinâ€associated dilated cardiomyopathy without severe skeletal myopathy. European Journal of Heart Failure, 2021, 23, 1276-1286.	7.1	14
95	Prognostic factors of infective endocarditis in patients on hemodialysis: A case series from a National Multicenter Registry. International Journal of Cardiology, 2017, 241, 295-301.	1.7	13
96	Combination of late gadolinium enhancement and genotype improves prediction of prognosis in nonâ€ischaemic dilated cardiomyopathy. European Journal of Heart Failure, 2022, 24, 1183-1196.	7.1	13
97	Endocarditis in patients with ascending aortic prosthetic graft: a case series from a national multicentre registry. European Journal of Cardio-thoracic Surgery, 2016, 50, 1149-1157.	1.4	12
98	A simple core dataset and disease severity score for hereditary transthyretin (ATTRv) amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 189-198.	3.0	12
99	Characterization of the MHC class I-related MR1 locus in nonhuman primates. Immunogenetics, 2001, 53, 643-648.	2.4	11
100	CaracterÃsticas clÃnicas y pronÃ³stico de la enfermedad de Danon. AnÃ¡lisis del registro multicÃ©ntrico espaÃ±ol. Revista Espanola De Cardiologia, 2019, 72, 479-486.	1.2	11
101	Identification of a peripheral blood gene signature predicting aortic valve calcification. Physiological Genomics, 2020, 52, 563-574.	2.3	11
102	The SRSF4â€“GAS5-Glucocorticoid Receptor Axis Regulates Ventricular Hypertrophy. Circulation Research, 2021, 129, 669-683.	4.5	11
103	Usefulness of Genetic Testing in Hypertrophic Cardiomyopathy: an Analysis Using Real-World Data. Journal of Cardiovascular Translational Research, 2017, 10, 35-46.	2.4	10
104	Role of echocardiography in the diagnosis and management of hypertrophic cardiomyopathy. Heart, 2018, 104, 261-273.	2.9	10
105	Clinical profile and outcome of cardiac amyloidosis in a Spanish referral center. Revista Espanola De Cardiologia (English Ed), 2021, 74, 149-158.	0.6	10
106	Rationale and design of a multicentre, prospective, randomised, controlled clinical trial to evaluate the efficacy of the adipose graft transposition procedure in patients with a myocardial scar: the AGTP II trial. BMJ Open, 2017, 7, e017187.	1.9	9
107	Prognostic Impact and Predictors of Ejection Fraction Recovery in Patients With Alcoholic Cardiomyopathy. Revista Espanola De Cardiologia (English Ed), 2018, 71, 612-619.	0.6	9
108	Clinical Findings and Prognosis of Danon Disease. An Analysis of the Spanish Multicenter Danon Registry. Revista Espanola De Cardiologia (English Ed), 2019, 72, 479-486.	0.6	9

#	Article	IF	Citations
109	POT1 and Damage Response Malfunction Trigger Acquisition of Somatic Activating Mutations in the VEGF Pathway in Cardiac Angiosarcomas. Journal of the American Heart Association, 2019, 8, e012875.	3.7	8
110	Sex Differences in Wild-Type Transthyretin Amyloidosis: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS). Cardiology and Therapy, 2022, 11, 393-405.	2.6	7
111	Late-onset angioedema due to an angiotensin-converting enzyme inhibitor. Canadian Journal of Cardiology, 2007, 23, 315-316.	1.7	6
112	Extracellular Volume Detects Amyloidotic Cardiomyopathy and Correlates With Neurological Impairment in Transthyretin-familial Amyloidosis. Revista Espanola De Cardiologia (English Ed), 2016, 69, 923-930.	0.6	6
113	Lafora Disease Is an Inherited Metabolic Cardiomyopathy. Journal of the American College of Cardiology, 2017, 69, 3007-3009.	2.8	6
114	Negative screening of Fabry disease in patients with conduction disorders requiring a pacemaker. Orphanet Journal of Rare Diseases, 2019, 14, 170.	2.7	6
115	Transthyretin amyloid cardiomyopathy. Medicina ClÃnica (English Edition), 2021, 156, 126-134.	0.2	6
116	Are 18F-fluorodeoxyglucose positron emission tomography results reliable in patients with ascending aortic grafts? A prospective study in non-infected patients. European Journal of Cardio-thoracic Surgery, 2021, 60, 148-154.	1.4	6
117	Adverse clinical course and poor prognosis of hypertrophic cardiomyopathy due to mutations in FHL1. International Journal of Cardiology, 2015, 191, 194-197.	1.7	5
118	A Descriptive Analysis of ATTR Amyloidosis in Spain from the Transthyretin Amyloidosis Outcomes Survey. Neurology and Therapy, 2021, 10, 833-845.	3.2	5
119	Cardiac Transplantation in Danon Disease. Journal of Cardiac Failure, 2022, 28, 664-669.	1.7	5
120	Usefulness of Genetic Testing for Hypertrophic Cardiomyopathy in Real-world Practice. Revista Espanola De Cardiologia (English Ed), 2013, 66, 746-747.	0.6	3
121	AplicaciÃ³n prÃ¡ctica de la genÃ©tica en el manejo de las miocardiopatÃas. Cardiocore, 2014, 49, 52-58.	0.0	3
122	Saw-Tooth Cardiomyopathy. JACC: Case Reports, 2020, 2, 1210-1211.	0.6	3
123	Health and economic impact of the correct diagnosis of transthyretin cardiac amyloidosis in Spain. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 1127-1133.	1.4	3
124	Early Preventive Treatment With Enalapril Improves Cardiac Function and Delays Mortality in Mice With Arrhythmogenic Right Ventricular Cardiomyopathy Type 5. Circulation: Heart Failure, 2021, 14, e007616.	3.9	3
125	Usefulness of natriuresis to predict in-hospital diuretic resistance. American Journal of Cardiovascular Disease, 2020, 10, 350-355.	0.5	3
126	Effect of shear stress on plaque rupture. Canadian Journal of Cardiology, 2007, 23, 396.	1.7	2

#	Article	IF	Citations
127	Tratamiento endovascular de complicaciones tardÃas tras la reparaciÃ³n quirÃºrgica de la coartaciÃ³n aÃ³rtica. Revista Espanola De Cardiologia, 2010, 63, 473-477.	1.2	2
128	Comments on the ESC Guidelines on the Management of Cardiovascular Diseases During Pregnancy. A Critical Vision of Spanish Cardiology. Revista Espanola De Cardiologia (English Ed), 2012, 65, 113-118.	0.6	2
129	MiocardiopatÃas mitocondriales asociadas a la mutaciÃ³n m.3243A>G en el gen MT-TL1: dos caras de la misma moneda. Revista Espanola De Cardiologia, 2015, 68, 153-155.	1.2	2
130	Myocardial Extracellular Volume Is Not Associated With Malignant Ventricular Arrhythmias in High-risk Hypertrophic Cardiomyopathy. Revista Espanola De Cardiologia (English Ed), 2017, 70, 933-940.	0.6	2
131	Systolic Dysfunction in Infarcted Mice Does Not Necessarily Lead to Heart Failure: Need to Refine Preclinical Models. Journal of Cardiovascular Translational Research, 2017, 10, 499-501.	2.4	2
132	Estrategias en congestiÃ³n refractaria: efectos del suero salino hipertÃ³nico en insuficiencia cardiaca aguda. REC: CardioClinics, 2019, 54, 55-57.	0.1	2
133	Screening of Fabry Disease in Patients with Chest Pain Without Obstructive Coronary Artery Disease. Journal of Cardiovascular Translational Research, 2021, 14, 948-950.	2.4	2
134	Temporal Trends of Wild-type Attr Amyloidosis in the Transthyretin Amyloidosis Outcomes Survey. Journal of Cardiac Failure, 2020, 26, S82.	1.7	2
135	Endovascular Treatment of Long-Term Complications Following Surgical Repair of Aortic Coarctation. Revista Espanola De Cardiologia (English Ed), 2010, 63, 473-477.	0.6	1
136	Familial Approach in Hereditary Transthyretin Cardiac Amyloidosis. Revista Espanola De Cardiologia (English Ed), 2011, 64, 523-526.	0.6	1
137	Amyloidosis. Also a Heart Disease. Revista Espanola De Cardiologia (English Ed), 2011, 64, 797-808.	0.6	1
138	Recommendations regarding diagnosis and treatment of transthyretin familial amyloid polyneuropathy. Medicina ClÃnica (English Edition), 2015, 145, 211-217.	0.2	1
139	Aortic composite tube valve graft infection due to Streptococcus pneumoniae. Journal of Nuclear Cardiology, 2016, 23, 168-169.	2.1	1
140	The p.Arg118Cys Variant in the GLA Gene Does Not Cause Fabry Disease. More Evidence. Revista Espanola De Cardiologia (English Ed), 2018, 71, 871-873.	0.6	1
141	Efficacy and Safety of Tafamidis Doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT). Journal of Cardiac Failure, 2019, 25, S77-S78.	1.7	1
142	Endomyocardial biopsy-confirmed myocarditis and inflammatory cardiomyopathy: clinical profile and prognosis. Revista Espanola De Cardiologia (English Ed), 2022, , .	0.6	1
143	Response to ECG, May 2015. Revista Espanola De Cardiologia (English Ed), 2015, 68, 530.	0.6	0
144	Mitochondrial Cardiomyopathies Associated With the m.3243A>G Mutation in the MT-TL1 Gene: Two Sides of the Same Coin. Revista Espanola De Cardiologia (English Ed), 2015, 68, 153-155.	0.6	0

#	Article	IF	Citations
145	Respuesta al ECG de mayo de 2015. Revista Espanola De Cardiologia, 2015, 68, 530.	1.2	0
146	ECG de mayo de 2015. Revista Espanola De Cardiologia, 2015, 68, 439.	1.2	0
147	ECG, May 2015. Revista Espanola De Cardiologia (English Ed), 2015, 68, 439.	0.6	0
148	Endophthalmitis and a Heart Murmur. Revista Espanola De Cardiologia (English Ed), 2015, 68, 804.	0.6	0
149	Familial Paralysis of the Atrium Due to a Mutation in SCN5A. Revista Espanola De Cardiologia (English) Tj ETQq1 1 0.784314 rgBT /Ov	0.6	0
150	Reversible dilated cardiomyopathy: into the thaumaturgy of the heart - Part 2. Neurology International, 2016, 6, .	0.5	0
151	Nanomechanical Phenotypes in Hypertrophic Cardiomyopathy caused by Missense Mutations in Cardiac Myosin-Binding Protein C. Biophysical Journal, 2017, 112, 164a-165a.	0.5	0
152	Crystallographic Structures of Titin Immunoglobulin-Like I21 Domains Involved in Dilated Cardiomyopathy. Biophysical Journal, 2021, 120, 252a.	0.5	0
153	Apical myectomy in patients with apical hypertrophic cardiomyopathy and advanced heart failure. Revista Espanola De Cardiologia (English Ed), 2021, 74, 554-555.	0.6	0
154	The Coronary Circulation in Cardiomyopathies and Cardiac Allografts. , 2017, , 119-135.		0
155	Prevalence, clinical profile and prognostic implications of interatrial block in patients admitted for heart failure. REC: CardioClinics, 2020, 55, 155-164.	0.1	0